Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab - DESQUAMATE

NCT05025813 is registered in ClinicalTrials.gov with Queensland Health as lead sponsor.

NCT NCT05025813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab - DESQUAMATE
Lead sponsor
Queensland Health
Phase
Phase 2
Overall status
Recruiting
Start date
June 28, 2022
Completion date
June 1, 2027
Enrollment
27 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma of the head and neck, head and neck cancer